Literature DB >> 29709970

Analysis of Human Parechovirus Genotypes in Yokohama District from 2000 to 2016.

Tomoko Soga Momoki1.   

Abstract

Human parechovirus (HPeV) infections in Yokohama City, Japan, were surveyed from 2000 to 2016. The sequence of the VP1 region of HPeVs was used to construct a phylogenetic tree and to reveal the putative amino acid (aa) sequences. Phylogenetic analysis showed the presence of 3 genotypes in Yokohama City: HPeV1 (25 specimens), HPeV3 (86 specimens), and HPeV4 (2 specimens). HPeV1 was detected nearly every year, with the highest number detected in 2014. HPeV3 was not detected until 2005, but was detected over a 1- or 3-yr period thereafter. HPeV1 was most prevalent from July to November, whereas HPeV3 peaked in July and August each year. HPeV1 was mainly detected in patients with infectious gastroenteritis or respiratory tract infections. In contrast, 87% of HPeV3-positive cases were in patients less than 2 months of age with a viral-induced fever. An analysis of the aa sequence of VP1 revealed a divergence within the same HPeV genotype, which was useful in analyzing the emergence and re-emergence of HPeV infections during the survey period. These findings suggest that molecular analysis of HPeVs may contribute to a better understanding of its epidemiology.

Entities:  

Keywords:  genotype; human parechovirus; phylogenetic tree; surveillance; variation

Mesh:

Substances:

Year:  2018        PMID: 29709970     DOI: 10.7883/yoken.JJID.2017.490

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  1 in total

1.  Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic.

Authors:  Emi Takashita; Chiharu Kawakami; Tomoko Momoki; Miwako Saikusa; Kouhei Shimizu; Hiroki Ozawa; Makoto Kumazaki; Shuzo Usuku; Nobuko Tanaka; Ichiro Okubo; Hiroko Morita; Shiho Nagata; Shinji Watanabe; Hideki Hasegawa; Yoshihiro Kawaoka
Journal:  Influenza Other Respir Viruses       Date:  2021-03-14       Impact factor: 4.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.